PMID- 35685555
OWN - NLM
STAT- MEDLINE
DCOM- 20220613
LR  - 20221207
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 2022
DP  - 2022
TI  - Efficacy of Pharmaceutical Care in Patients with Type 2 Diabetes Mellitus and 
      Hypertension: A Randomized Controlled Trial.
PG  - 7681404
LID - 10.1155/2022/7681404 [doi]
LID - 7681404
AB  - BACKGROUND: The rates of treatment adherence and treat-to-target rates of blood 
      pressure and blood glucose-related indexes in patients with hypertension and type 
      2 diabetes mellitus (T2DM) are associated with prognosis. This study aimed to 
      investigate the efficacy of pharmaceutical care postdischarge for treatment 
      adherence in hypertensive patients with type 2 diabetes mellitus (T2DM). METHODS: 
      This was a randomized controlled trial of patients with combined T2DM and 
      hypertension treated between January and May 2018. Pharmaceutical care included 
      free access to a clinical pharmacist, education material, a WeChat account for 
      live discussion, and a telephone follow-up. The primary endpoint was the 3-month 
      medication adherence. The secondary endpoints included the achieving levels of 
      target rates and values of fasting plasma glucose (FPG), 2 h postprandial glucose 
      (2hPG), and hemoglobin A1c (HbA1c) and the rates of reaching the achieving target 
      rate of blood pressure target <130/80. RESULTS: In 80 participants, the 3-month 
      medication adherence was higher in the pharmaceutical care group than the routine 
      group (90.0% vs. 52.5%, P < 0.001). In terms of FPG, 2hPG, and HbA1c, there were 
      also significant differences between the pharmaceutical care and routine groups 
      (FPG, 6.50 (6.00, 7.18) vs. 7.00 (6.83, 7.78) mmol/L, P=0.004; 2hPG, 8.45 (7.45, 
      9.28) vs. 9.35 (8.23, 10.15), P=0.007; HbA1c, 6.5% (6.3%, 7.0%) vs. 7.0% (6.5%, 
      7.4%), P=0.007). The achieving target rate of reaching the blood pressure target 
      in the pharmaceutical care group (92.5%) was significantly higher than that in 
      the routine group (62.5%; P < 0.05). CONCLUSION: The postdischarge pharmaceutical 
      care program in patients with T2DM and hypertension improves medication 
      adherence.
CI  - Copyright (c) 2022 Weibo Wang et al.
FAU - Wang, Weibo
AU  - Wang W
AUID- ORCID: 0000-0003-1443-4670
AD  - Department of Pharmacy, Dongying People's Hospital, Dongying, China.
FAU - Geng, Lijuan
AU  - Geng L
AUID- ORCID: 0000-0002-8490-2663
AD  - Department of Pharmacy, The Second People's Hospital of Dongying, Dongying, 
      China.
FAU - Sun, Chenjing
AU  - Sun C
AUID- ORCID: 0000-0003-0916-5541
AD  - Department of Pharmacy, Dongying People's Hospital, Dongying, China.
FAU - Li, Hui
AU  - Li H
AUID- ORCID: 0000-0003-4245-6332
AD  - Department of Quality Management, Dongying People's Hospital, Dongying, China.
FAU - Wang, Jinying
AU  - Wang J
AUID- ORCID: 0000-0003-1227-5637
AD  - Department of Pharmacy, Dongying People's Hospital, Dongying, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220324
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - Aftercare
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - *Hypertension/drug therapy
MH  - Patient Discharge
MH  - *Pharmaceutical Services
PMC - PMC9159207
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/06/11 06:00
MHDA- 2022/06/14 06:00
PMCR- 2022/03/24
CRDT- 2022/06/10 02:32
PHST- 2021/12/17 00:00 [received]
PHST- 2022/03/12 00:00 [accepted]
PHST- 2022/06/10 02:32 [entrez]
PHST- 2022/06/11 06:00 [pubmed]
PHST- 2022/06/14 06:00 [medline]
PHST- 2022/03/24 00:00 [pmc-release]
AID - 10.1155/2022/7681404 [doi]
PST - epublish
SO  - Int J Clin Pract. 2022 Mar 24;2022:7681404. doi: 10.1155/2022/7681404. 
      eCollection 2022.